TCI Wealth Advisors’s Keros Therapeutics KROS Stock Holding History

TCI Wealth Advisors’s Portfolio KROS Stock Details KROS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-73	Closed	-$3.12K	–	1276
2023 Q1	$3.12K	Buy	+73	New	+$3.69K	﹤0.01%	1836
2022 Q2	–	Sell	-76	Closed	-$4K	–	2405
2022 Q1	$4K	Buy	+76	New	+$3.9K	﹤0.01%	1724
2021 Q2	–	Sell	-30	Closed	-$2K	–	2386
2021 Q1	$2K	Buy	+30	New	+$1.9K	﹤0.01%	1788

Other funds holding KROS

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

TCI Wealth Advisors's KROS Position: Q2 2023 in Review

TCI Wealth Advisors sold out of Keros Therapeutics (KROS) in Q2 2023, closing a stake of 73 shares — an estimated $3.12K sold.

TCI Wealth Advisors first reported a position in KROS in Q1 2021 and held it in 3 quarters. The position peaked at $4K in Q1 2022. 123 funds tracked by Wall St. Rank hold KROS as of Q2 2023.

TCI Wealth Advisors reported no remaining Keros Therapeutics position as of Q2 2023 after selling out during the quarter.
TCI Wealth Advisors sold 73 Keros Therapeutics shares in Q2 2023, an estimated $3.12K.
TCI Wealth Advisors first reported a position in Keros Therapeutics in Q1 2021 and held it in 3 quarters.
TCI Wealth Advisors's Keros Therapeutics position peaked at $4K in Q1 2022.
123 funds tracked by Wall St. Rank held Keros Therapeutics as of Q2 2023.

Based on TCI Wealth Advisors's 13F filing for Q2 2023, filed 4 Aug 2023.